二叔丁基萘磺酸 | 67970-30-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 二叔丁基萘磺酸
• 英文名称: 2,3-DI-Tert-butylnaphthalene-1-sulfonic acid
• 英文别名: 2,3-ditert-butylnaphthalene-1-sulfonic acid
• CAS: 67970-30-3
• 化学式: C₁₈H₂₄O₃S
• 分子量: 320.4
• InChiKey: RSOAMRXKGHCGNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• SALTS OF HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
  申请人：Board of Regents, University of Texas System

  公开号：US20150239876A1

  公开（公告）日：2015-08-27

  The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

  本公开涉及杂环化合物的盐和抑制HIF通路活性的方法。这些化合物被设计用于治疗或预防癌症和其他缺氧介导的疾病。
• SALT AND CRYSTAL OF TRIAZOLOPYRAZINE DERIVATIVE
  申请人：ASTELLAS PHARMA INC.

  公开号：US20210094955A1

  公开（公告）日：2021-04-01

  [Problem] Provided are a salt of (4-fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]methanone, and a crystal of the salt. [Element for Solution] Salts of (4-fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]methanone with various acids have been studied. As a result, a pharmaceutically acceptable salt of the compound and a crystal of the salt have been found. That is, the present invention relates to a salt of the compound and a crystal of the salt. Furthermore, the present invention relates to a pharmaceutical composition including a salt of the compound or a crystal of the salt, and one or more excipients.

  【问题】提供一种[(8R)-8-甲基-3-(3-甲基-1,2,4-噻二唑-5-基)-5,6-二氢[1,2,4]三唑并[4,3-a]吡嗪-7(8H)-基]甲酮的(4-氟苯基)盐和该盐的晶体。【解决方案】研究了(4-氟苯基)[(8R)-8-甲基-3-(3-甲基-1,2,4-噻二唑-5-基)-5,6-二氢[1,2,4]三唑并[4,3-a]吡嗪-7(8H)-基]甲酮与各种酸的盐。结果发现了化合物的药学上可接受的盐和该盐的晶体。即，本发明涉及化合物的盐和该盐的晶体。此外，本发明涉及包括化合物的盐或该盐的晶体以及一种或多种赋形剂的药物组合物。
• [EN] USP7 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF<br/>[FR] MOLÉCULES CHIMÉRIQUES CIBLANT LA SURVIE (SURTAC) SE LIANT À USP7 ET LEURS UTILISATIONS
  申请人：LOCKI THERAPEUTICS LTD

  公开号：WO2022148821A1

  公开（公告）日：2022-07-14

  Chimeric molecules that include a USP7 binding domain and uses thereof for deubiquitinating a ubiquitinylated protein, and or for treating a disease in a subject in need are provided herein. Further, Survival-Targeting Chimeric (SURTAC) molecules that include a USP7 binding domain linked to a target protein binding domain are disclosed herein, as are their uses for deubiquitination and treating disease. In some instances, the target protein is a ubiquitinylated protein, wherein a bound USP7 enzyme may proteolytically remove ubiquitin from the target ubiquitinylated protein.

  本文提供了包含USP7结合域的嵌合分子及其用途，用于去泛素化泛素化蛋白质或治疗需要的主体的疾病。此外，本文还公开了包括USP7结合域连接到目标蛋白质结合域的Survival-TArgeting Chimeric（SURTAC）分子及其用途，用于去泛素化和治疗疾病。在某些情况下，目标蛋白质是泛素化蛋白质，其中结合的USP7酶可以通过蛋白酶作用从目标泛素化蛋白质中去除泛素。
• [EN] USP5 BINDING SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES & USES THEREOF<br/>[FR] MOLÉCULES CHIMÉRIQUES VISANT LA SURVIE ET SE LIANT À USP5 (SURTAC) ET LEURS UTILISATIONS
  申请人：LOCKI THERAPEUTICS LTD

  公开号：WO2022148822A1

  公开（公告）日：2022-07-14

  Chimeric molecules that include a USP5 binding domain and uses thereof for deubiquitinating a ubiquitinylated protein, and or for treating a disease in a subject in need are provided herein. Further, Survival-Targeting Chimeric (SURTAC) molecules that include a USP5 binding domain linked to a target protein binding domain are disclosed herein, as are their uses for deubiquitination and treating disease. In some instances, the target protein is a ubiquitinylated protein, wherein a bound USP5 enzyme may proteolytically remove ubiquitin from the target ubiquitinylated protein.

  本文提供了包括USP5结合域的嵌合分子，以及其用于去泛素化泛素化蛋白质或治疗需要治疗的主体的用途。此外，本文还披露了包括USP5结合域连接到目标蛋白质结合域的Survival-TArgeting Chimeric（SURTAC）分子，以及它们用于去泛素化和治疗疾病的用途。在某些情况下，目标蛋白质是泛素化蛋白质，其中结合的USP5酶可以蛋白水解地从目标泛素化蛋白质中去除泛素。
• Salts of heterocyclic modulators of HIF activity for treatment of disease
  申请人：Board of Regents, The University of Texas System

  公开号：US10363248B2

  公开（公告）日：2019-07-30

  The present disclosure relates to salts of heterocyclic compounds and methods that inhibit HIF pathway activity. The compounds are designed to treat or prevent cancer and other hypoxia-mediated diseases.

  本公开涉及抑制 HIF 通路活性的杂环化合物盐和方法。这些化合物旨在治疗或预防癌症和其他缺氧介导的疾病。